Table 2.
Study 208 (Eribulin + Trastuzumab in HER2+ MBC): demographics and baseline characteristics
| With prior anthracycline (n = 11) | With prior taxane (n = 23) | With prior anthracycline and taxane (n = 9) | Without prior anthracycline or taxane (n = 27) | |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Female | 11 (100) | 23 (100) | 9 (100) | 26 (96) |
| Male | 0 | 0 | 0 | 1 (4) |
| Age (years) | ||||
| Mean (SD) | 57 (12) | 60 (11) | 58 (12) | 58 (11) |
| Age group, n (%) | ||||
| <50 years | 4 (36) | 5 (22) | 3 (33) | 5 (19) |
| 50–65 years | 3 (27) | 8 (35) | 2 (22) | 15 (56) |
| ≥65 years | 4 (36) | 10 (43) | 4 (44) | 7 (26) |
| Age at diagnosis (years) | ||||
| Mean (SD) | 51 (14) | 56 (12) | 54 (14) | 58 (11) |
| Estrogen receptor (ER) status | ||||
| + | 7 (64) | 14 (61) | 6 (67) | 20 (74) |
| – | 3 (27) | 9 (39) | 3 (33) | 7 (26) |
| Not done | 1 (9) | 0 | 0 | 0 |
| Progesterone receptor (PR) status | ||||
| + | 5 (45) | 10 (43) | 4 (44) | 11 (41) |
| – | 5 (45) | 13 (57) | 5 (56) | 16 (59) |
| Not done | 1 (9) | 0 | 0 | 0 |
| HER2 status, n (%) | ||||
| + | 11 (100) | 23 (100) | 9 (100) | 27 (100) |
| – | 0 | 0 | 0 | 0 |
SD standard deviation